- Poster presentation
- Open Access
Natural immunomodulator preimplantation factor PIF affected cancer growth in malignant melanomas
© Kotlan et al; licensee BioMed Central Ltd. 2014
- Published: 6 May 2014
- Melanoma Cell
- Metastatic Melanoma
- Static Magnetic Field
- Trophoblastic Cell
Malignant and trophoblastic cells share common features in terms of migration and invasion, while they represent striking differences also (1). Our results on immune mechanisms in pregnancy failure (2) and use of immunotherapeutics (3) fostered the present new approach: Pregnancy derived compounds for potential growth controlling effect in metastatic melanomas were studied.
Preimplantation factor (PIF), a novel peptide secreted by viable embryos was selected (4), as its immune regulatory effects were advantageous (5). Based on our tumorimmunological project (Ethical permission ETT TUKEB 1642-02/2010), minor tissue samples from surgically removed lymphnodes of patients with metastatic melanomas were processed. Primary cultures were set up in special conditions with or without immunomodulatory PIF. In a parallel system, we transfused human HT199 melanoma cells into immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice and followed tumor burden in PIF-treated groups.
We found that PIF treatment delayed tumor outgrowth in time. A tendency of lower tumor volumes was seen both after administration of immunomodulator peptide and use of additional physical (static magnetic field) treatment. A synergistic effect could be achieved by this combination treatment strategy. Retained or primed expression of glycolipid based tumorassociated antigens on PIF treated melanoma cells could be defined by immunofluorescence FACS and confocal laser microscopy.
Our results suggest an indirect mechanism of PIF on tumor growth. Retained or enhanced tumor antigen expression is advantageous, as cancerous cells become predisposed to be recognized, while induced activation of antigen presenting cells is beneficial for elimination. Our complementary strategy resulted as effective and provides a new potential modality for cancer control.
HJLCT Melanoma Research Award/B.K./2010, INNO 08-3-2009-024899/J.T./2010, TÁMOP-4.2.2.C-11/1/KONV-2012-0001/J.F.L./2013, BioIncept LLC sPIF (proprietary)
- Perry JK, Lins RJ, Lobie PE, Mitchell MD: Regulation of invasive growth: similar epigenetic mechanisms underpin tumour progression and implantation in human pregnancy. Clin Sci (Lond). 2009, 118: 451-457. 10.1042/CS20090503.View ArticleGoogle Scholar
- Kotlan B, Padanyi A, Batorfi J, Fulop V, Szigetvari I, Rajczy K, Pénzes M, Gyódi E, Réti M, Petranyi Gy: Alloimmune and autoimmune background in recurrent pregnancy loss – succesful immunotherapy by intravenous immunoglobulin. American Journal of Reproductive Immunology. 2006, 55: 331-340. 10.1111/j.1600-0897.2006.00368.x.View ArticlePubMedGoogle Scholar
- Kotlan B, Stroncek DF, Marincola FM: Intravenous immunoglobulin - based immunotherapy: An arsenal of possibilities for patients and science. Review Immunotherapy. 2009, 1 (6): 995-1014. 10.2217/imt.09.67.View ArticlePubMedGoogle Scholar
- Roussev RG, Coulam CB, Kaider BD, Yarkoni M, Leavis PC, Barnea ER: Embryonic origin of preimplantation factor (PIF): biological activity and partial characterization. Molecular Human Reproduction. 1996, 2: 883-887. 10.1093/molehr/2.11.883.View ArticlePubMedGoogle Scholar
- Barnea ER, Kirk D, Ramu S, Rivnay B, Roussev R, Paidas MJ: Preimplantation factor orchestrates systemic antiinflamatory response by immune cells: effect on peripheral blood mononuclear cells. Am. J Obstet. Gynecol. 2012, 207 (4): 313.e1-313.e11.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.